TCL Archive Secondary AML In High-Dose Chemo Trial Cause For Careful Monitoring, NCI Says August 19, 1994
TCL Archive FDA Committee Okays Leuprolide NDA, But Recommends Against Mitoxantrne, Epirubicin April 5, 1985
TCL Archive Updated EMILIA Phase III Trial Results Confirm Increase in Overall Survival August 31, 2012